[Translated article] Spanish Asthma Management Guidelines (GEMA) v.5.1. Highlights and Controversies

Vicente Plaza; Isam Alobid; Cesáreo Alvarez; Marina Blanco; Jorge Ferreira; Gabriel García; Antonio Gómez-Outes; Fernando Gómez; Antonio Hidalgo; Javier Korta; Jesús Molina; Francisco Javier Pellegrini; Montserrat Pérez; Javier Plaza; Manuel Praena; Santiago Quirce; José Sanz

doi:10.1016/j.arbres.2021.05.032

[Translated article] Spanish Asthma Management Guidelines (GEMA) v.5.1. Highlights and Controversies

Vicente Plaza, Isam Alobid, Cesáreo Alvarez, Marina Blanco, Jorge Ferreira, Gabriel García, Antonio Gómez-Outes, Fernando Gómez, Antonio Hidalgo, Javier Korta, Jesús Molina, Francisco Javier Pellegrini, Montserrat Pérez, Javier Plaza, Manuel Praena, Santiago Quirce, José Sanz

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

Abstract

In this fifth phase of development, the contents of the Spanish Asthma Management Guidelines (GEMA), which include versions 5.0 and 5.1, have undergone a thorough review. The aim here is to set the main changes in context. These could be summarized as follows: DIAGNOSIS: new FE NO cut-off and severity classification based on treatment needed to maintain control; INTERMITTENT ASTHMA: a more restrictive concept and treatment extended to include a glucocorticoid/adrenergic combination as needed; MILD ASTHMA: glucocorticoid/adrenergic therapy as needed as an alternative in case of low therapeutic adherence to conventional fixed-dose steroids; SEVERE ASTHMA: readjustment of phenotypes, incorporation of triple therapy in a single inhaler, and criteria for selection of a biologic in severe uncontrolled asthma; OTHERS: specific scoring in childhood asthma, incorporation of certain organizational aspects (care circuits, asthma units, telemedicine), new sections on COVID-19 and nasal polyposis.

Original language	English
Pages (from-to)	T150-T158
Journal	Archivos de bronconeumologia
Volume	58
Issue number	2
DOIs	https://doi.org/10.1016/j.arbres.2021.05.032
Publication status	Published - Feb 2022

Keywords

Adrenergic Agents/therapeutic use
Asthma/drug therapy
COVID-19
Glucocorticoids/therapeutic use
Humans

Access to Document

10.1016/j.arbres.2021.05.032Licence: C In Copyright

Cite this

Plaza, V., Alobid, I., Alvarez, C., Blanco, M., Ferreira, J., García, G., Gómez-Outes, A., Gómez, F., Hidalgo, A., Korta, J., Molina, J., Pellegrini, F. J., Pérez, M., Plaza, J., Praena, M., Quirce, S., & Sanz, J. (2022). [Translated article] Spanish Asthma Management Guidelines (GEMA) v.5.1. Highlights and Controversies. Archivos de bronconeumologia, 58(2), T150-T158. https://doi.org/10.1016/j.arbres.2021.05.032

@article{e1edbdf6648c415bb12fd025854f5ad3,

title = "[Translated article] Spanish Asthma Management Guidelines (GEMA) v.5.1. Highlights and Controversies",

abstract = "In this fifth phase of development, the contents of the Spanish Asthma Management Guidelines (GEMA), which include versions 5.0 and 5.1, have undergone a thorough review. The aim here is to set the main changes in context. These could be summarized as follows: DIAGNOSIS: new FE NO cut-off and severity classification based on treatment needed to maintain control; INTERMITTENT ASTHMA: a more restrictive concept and treatment extended to include a glucocorticoid/adrenergic combination as needed; MILD ASTHMA: glucocorticoid/adrenergic therapy as needed as an alternative in case of low therapeutic adherence to conventional fixed-dose steroids; SEVERE ASTHMA: readjustment of phenotypes, incorporation of triple therapy in a single inhaler, and criteria for selection of a biologic in severe uncontrolled asthma; OTHERS: specific scoring in childhood asthma, incorporation of certain organizational aspects (care circuits, asthma units, telemedicine), new sections on COVID-19 and nasal polyposis. ",

keywords = "Adrenergic Agents/therapeutic use, Asthma/drug therapy, COVID-19, Glucocorticoids/therapeutic use, Humans",

author = "Vicente Plaza and Isam Alobid and Ces{\'a}reo Alvarez and Marina Blanco and Jorge Ferreira and Gabriel Garc{\'i}a and Antonio G{\'o}mez-Outes and Fernando G{\'o}mez and Antonio Hidalgo and Javier Korta and Jes{\'u}s Molina and Pellegrini, {Francisco Javier} and Montserrat P{\'e}rez and Javier Plaza and Manuel Praena and Santiago Quirce and Jos{\'e} Sanz",

year = "2022",

month = feb,

doi = "10.1016/j.arbres.2021.05.032",

language = "English",

volume = "58",

pages = "T150--T158",

number = "2",

}

Plaza, V, Alobid, I, Alvarez, C, Blanco, M, Ferreira, J, García, G, Gómez-Outes, A, Gómez, F, Hidalgo, A, Korta, J, Molina, J, Pellegrini, FJ, Pérez, M, Plaza, J, Praena, M, Quirce, S & Sanz, J 2022, '[Translated article] Spanish Asthma Management Guidelines (GEMA) v.5.1. Highlights and Controversies', Archivos de bronconeumologia, vol. 58, no. 2, pp. T150-T158. https://doi.org/10.1016/j.arbres.2021.05.032

TY - JOUR

T1 - [Translated article] Spanish Asthma Management Guidelines (GEMA) v.5.1. Highlights and Controversies

AU - Plaza, Vicente

AU - Alobid, Isam

AU - Alvarez, Cesáreo

AU - Blanco, Marina

AU - Ferreira, Jorge

AU - García, Gabriel

AU - Gómez-Outes, Antonio

AU - Gómez, Fernando

AU - Hidalgo, Antonio

AU - Korta, Javier

AU - Molina, Jesús

AU - Pellegrini, Francisco Javier

AU - Pérez, Montserrat

AU - Plaza, Javier

AU - Praena, Manuel

AU - Quirce, Santiago

AU - Sanz, José

PY - 2022/2

Y1 - 2022/2

N2 - In this fifth phase of development, the contents of the Spanish Asthma Management Guidelines (GEMA), which include versions 5.0 and 5.1, have undergone a thorough review. The aim here is to set the main changes in context. These could be summarized as follows: DIAGNOSIS: new FE NO cut-off and severity classification based on treatment needed to maintain control; INTERMITTENT ASTHMA: a more restrictive concept and treatment extended to include a glucocorticoid/adrenergic combination as needed; MILD ASTHMA: glucocorticoid/adrenergic therapy as needed as an alternative in case of low therapeutic adherence to conventional fixed-dose steroids; SEVERE ASTHMA: readjustment of phenotypes, incorporation of triple therapy in a single inhaler, and criteria for selection of a biologic in severe uncontrolled asthma; OTHERS: specific scoring in childhood asthma, incorporation of certain organizational aspects (care circuits, asthma units, telemedicine), new sections on COVID-19 and nasal polyposis.

AB - In this fifth phase of development, the contents of the Spanish Asthma Management Guidelines (GEMA), which include versions 5.0 and 5.1, have undergone a thorough review. The aim here is to set the main changes in context. These could be summarized as follows: DIAGNOSIS: new FE NO cut-off and severity classification based on treatment needed to maintain control; INTERMITTENT ASTHMA: a more restrictive concept and treatment extended to include a glucocorticoid/adrenergic combination as needed; MILD ASTHMA: glucocorticoid/adrenergic therapy as needed as an alternative in case of low therapeutic adherence to conventional fixed-dose steroids; SEVERE ASTHMA: readjustment of phenotypes, incorporation of triple therapy in a single inhaler, and criteria for selection of a biologic in severe uncontrolled asthma; OTHERS: specific scoring in childhood asthma, incorporation of certain organizational aspects (care circuits, asthma units, telemedicine), new sections on COVID-19 and nasal polyposis.

KW - Adrenergic Agents/therapeutic use

KW - Asthma/drug therapy

KW - COVID-19

KW - Glucocorticoids/therapeutic use

KW - Humans

U2 - 10.1016/j.arbres.2021.05.032

DO - 10.1016/j.arbres.2021.05.032

M3 - Article

C2 - 35971814

VL - 58

SP - T150-T158

IS - 2

ER -

[Translated article] Spanish Asthma Management Guidelines (GEMA) v.5.1. Highlights and Controversies

Abstract

Keywords

Access to Document

Fingerprint

Cite this